Single foci prostate cancer: Current diagnosis and management

Current Urology

Volumn 7, Issue 1, 2013, Pages 1-6

  Efthimiou, Ioannis ^a   Skrepetis, Konstadinos ^a   Bournia, Elefteria ^a  

^a Kalamata General Hospital   (Greece)

Author keywords

Prostate cancer; Single foci

Indexed keywords

CANCER DIAGNOSIS; CANCER GRADING; COMORBIDITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; NEEDLE BIOPSY; PATHOLOGIST; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; UROLOGIST; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; IMMUNOREACTIVITY; LIPID METABOLISM; PERINEURAL INVASION; SINGLE FOCI PROSTATE CANCER;

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN; FATTY ACID SYNTHASE; GOLGI MEMBRANE PROTEIN 1; PHOSPHOPROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

EID: 84883189659     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000343544     Document Type: Review

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Johansson JE: Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994;152:1753-1756.
3. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J: Results of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
4. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA: Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998;11:543-551.
5. Weldon VE, Tavel FR, Neuwirth H, Cohen R: Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995;154:1074-1077.
6. Zackrisson B, Aus G, Bergdahl, Lilja H, Lodding P, Pihl CG, Hugosson J: The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004;171:1500-1503.
7. Allan RW, Sanderson H, Epstein JI: Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003; 170:370-372.
8. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005;48:895-899.
9. Epstein JI: Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17:307-315.
10. Van der Kwast T, Wolters T, Evans A, Roobol M: Single prostate cancer foci on prostate biopsy. Eur Urol Suppl 2008;7:549-556.
11. Efthimiou I, Skrepetis K, Bournia E: A clinical dilemma; single prostatic ancer focus in biopsy. Interpretation and management. J BUON 2010;15:19-24.
12. Leroy X, Aubert S, Villers A, Ballereau C, Augusto D, Gosselin B: Minimal focus of adenocarcinoma on prostate biopsy: clinico-pathological correlations. J Clin Pathol 2003; 56:230-232.
13. Thorson P, Humphrey PA: Minimal adeno-carcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000;114:896-909.
14. Algaba F, Epstein J, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I: Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for diagnosis of cancer in biopsy material. Cancer 1996;78: 376-381.
15. Thorson P, Vollmer RT, Arcangeli C, et al: Minimal adenocarcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998;11:543-551.
16. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ: False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 2010;34: 35-43.
17. Iczkowski KA: Current prostate biopsy interpretation: Criteria for cancer, atypical small acinar proliferation, high grade prostatic in-traepithelial neoplasia and use of immunos-tains. Arch Pathol Lab Med 2006;130:835-842.
18. Renshaw AA, Santis WF, Richie JP: Clinico-pathological characteristics of prostatic ad-enocarcinoma in men with atypical prostate needle biopsies. J Urol 1998;159:2018-2021.
19. Chan TY, Epstein JI: Patient and urologist driven second opinion of prostate needle biopsies. J Urol 2005;174:1390-1394.
20. Wojno KJ, Epstein JI: The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate carcinoma: a review of 228 cases. Am J Surg Pathol 1995;19:251-260.
21. Garcia FU, Haber MM, Chen X: Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype. Prostate 2007;67:1686-1692.
22. Kristiansen G: Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 2012;60:125-141.
23. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA: Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-1168.
24. Zhou M, Shah R, Shen R, Rubin MA: Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003;27:365-371.
25. Oliai BR, Kahane H, Epstein JI: Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 2002;26:1151-1160.
26. Ali TZ, Epstein JI: False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immu-nomarker for basal cells. Am J Surg Pathol 2008;32:1890-1895.
27. Humphrey PA: Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007;60:35-42.
28. Murphy AJ, Hughes CA, Lannigan G, Sheils O, O'Leary J, Loftus B: Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology 2007;50:243-251.
29. Gologan A, Bastacky S, McHale T, Yu J, Cai C, Monzon-Bordonaba F, Dhir R: Age-associated changes in alpha-methyl CoA race-mase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol 2005;29: 1435-1441.
30. Tischler V, Fritzsche FR, Gerhardt J, Jager C, Stephan C, Jung K, Dietel M, Moch H, Kristiansen G: Comparison of the diagnostic value of fatty acid synthase (FASN) with al-pha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. Histopatholo-gy 2010;56:811-815.
31. Wu X, Zayzafoon M, Zhang X, Hameed O: Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma? A comparison with AMACR. Am J Clin Pathol 2011;136:239-246.
32. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H: GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008;99:939-948.
33. Wise AM, Stamey TA, McNeal JE, Clayton JL: Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
34. Ahmed HU: The index lesion and the origin of prostate cancer. N Engl J Med 2009;361: 1704-1706.
35. Liu W, Laitinen S, Khan S, Vihinen M, Kow-alski J, Yu G, Chen L, Ewing CM, Eisen-berger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-565.
36. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-938.
37. Egevad L, Norberg M, Mattson S, Norlen BJ, Busch C: Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998;52:653-658.
38. Ochiai A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ: Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 2007;177:907-910.
39. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F: Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy"). Eur Urol 2006;50:666-674.
40. Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, Maccagnano C, Gallina A, Sacca A, Freschi M, Doglioni C, Rigatti P, Montorsi F: The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol 2011;60:834-841.
41. Abouassaly R, Tan N, Moussa A, Jones JS: Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol 2008;180:911-914.
42. Ching CB, Moussa AS, Li J, Lane BR, Zippe C, Jones JS: Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates. J Urol 2009;181:2077-2082.